Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy. [electronic resource]
Producer: 20151005Description: 604-9 p. digitalISSN:- 1873-2518
- Adolescent
- Antibodies, Bacterial -- blood
- Antirheumatic Agents -- therapeutic use
- Arthritis, Juvenile -- drug therapy
- Child
- Child, Preschool
- Enzyme-Linked Immunosorbent Assay
- Etanercept
- Female
- Humans
- Immunoglobulin G -- therapeutic use
- Male
- Methotrexate -- therapeutic use
- Pneumococcal Infections -- prevention & control
- Pneumococcal Vaccines -- administration & dosage
- Receptors, Tumor Necrosis Factor -- therapeutic use
- Treatment Outcome
- Tumor Necrosis Factor-alpha -- therapeutic use
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.